GlassScriptPhysician profile
Javier T Quesada
NPI 1215929880
$5,468.35
in general payments reported to CMS, 2019-2025
25 companies · $1,553 in 2025
The $1,553 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $592 · 2020: $235 · 2021: $276 · 2022: $355 · 2023: $579 · 2024: $1,878 · 2025: $1,553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,944 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,944.15 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,356.67 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Gilead Sciences, INC. | $804.70 | 2019-2025 | Vemlidy |
| Janssen Pharmaceuticals, INC | $502.28 | 2019-2022 | |
| Amgen INC. | $501.07 | 2023-2025 | Repatha, Repatha, Otezla |
| Astellas Pharma US INC | $345.87 | 2024-2025 | Veozah |
| Lilly USA, LLC | $345.32 | 2023-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.71 | 2019-2025 | Jardiance |
| Abbott Laboratories | $187.69 | 2022-2024 | Freestyle Libre 3 |
| Ardelyx, INC. | $161.62 | 2024 | Ibsrela |
| Idorsia Pharmaceuticals US INC | $158.07 | 2022-2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $148.02 | 2022-2025 | |
| Sanofi Pasteur INC. | $111.02 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $106.27 | 2024-2025 | Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.78 | 2019 | |
| Alkermes, INC. | $83.94 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $63.70 | 2024-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Dexcom, INC. | $55.17 | 2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $46.74 | 2019-2024 | |
| Phadia US INC. | $38.23 | 2023-2024 | Immunocap |
| Csl Behring | $30.70 | 2023 | Hizentra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.86 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $23.55 | 2023 | Farxiga |
| Hologic Sales and Service, LLC | $19.36 | 2019 | |
| Xeris Pharmaceuticals, INC. | $18.54 | 2025 | Gvoke Hypopen |
| Indivior INC. | $12.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Quesada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.